Vericel Corporation VCEL 深 沪
已收盘 05-15 16:00:00 美东时间
33.03
-0.110
-0.33%
华盛通- 最 高33.385
- 今 开32.79
- 成交量 44.90万股
- 最 低 32.25
- 昨 收 33.14
- 总市值 16.82亿
- 52周最高 45.97
- 市盈率 静 104.29
- 换手率 0.88%
- 52周最低 28.95
- 委 比 5.79%
- 总股本 5093.16万
- 历史最高 68.94
- 量 比 0.56
- 振 幅 3.42%
- 历史最低 1.11
- 每 手 1
- 风险率 3.35%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 爱彼迎、Affirm、CoreWeave、Datadog、微芯科技等获多家大行上调目标价；HubSpot惨遭14家大行下调目标价
今日重点评级关注：HC Wainwright & Co.：维持Artiva Biotherapeutics"买入"评级，目标价从15美元升至35美元；韦德布什：维持Cullinan Therapeutics"跑赢大市"评级，目标价从36美元升至37美元
05-11 15:43
财报速睇 | Vericel Corporation 2026财年Q1营收0.68亿美元，同比增长30.1%；归母净利润亏损0.06亿美元，同比亏损缩窄44.0%
华盛资讯5月7日讯，Vericel Corporation公布2026财年Q1业绩，公司Q1营收0.68亿美元，同比增长30.1%，归母净利润亏损0.06亿美元，同比亏损缩窄44.0%。
05-07 21:41
Vericel shares are trading higher after the company reported better-than-expected Q1 financial results and raised its FY26 sales guidance above estimates.
Vericel shares are trading higher after the company reported better-than-expect...
05-07 21:06
财报速睇 | Vericel Corporation 2026财年Q1营收0.68亿美元，同比增长30.1%；归母净利润亏损0.06亿美元，同比亏损缩窄44.0%
华盛资讯5月7日讯，Vericel Corporation公布2026财年Q1业绩，公司Q1营收0.68亿美元，同比增长30.1%，归母净利润亏损0.06亿美元，同比亏损缩窄44.0%。
05-07 20:19
Vericel Raises FY2026 Sales Guidance from $316.000M-$326.000M to $326.000M-$336.000M vs $323.377M Est
Vericel (NASDAQ:VCEL) raises FY2026 sales outlook from $316.000 million-$326.000 million to $326.000 million-$336.000 million vs $323.377 million estimate.
05-07 20:02
Vericel Shareholders Reaffirm Board, Pay Plan, Auditor
Vericel ( ($VCEL) ) has issued an announcement. At Vericel Corporation’s April ...
05-02 04:49
美股大行评级 | 大行互评！花旗银行、贝莱德获多家大行上调目标价；哈里伯顿、强生、Patterson获多家大行上调目标价
今日重点评级关注：Ascendiant Capital：维持Knightscope"买入"评级，目标价从25美元升至26美元；杰富瑞：维持Allogene疗法"买入"评级，目标价从6美元升至10美元
04-16 10:14
Truist Securities Maintains Buy on Vericel, Lowers Price Target to $42
Truist Securities analyst Richard Newitter maintains Vericel (NASDAQ:VCEL) with a Buy and lowers the price target from $48 to $42.
04-15 23:42
Vericel Corp. Awarded $196.8M HHS BARDA Contract For NonSurgical Debridement, Research And Development In Biotechnology (Except Nanobiotechnology)
https://sam.gov/opp/f339ca12b7e047cdac559fe926d1a190/view
04-03 01:07
Vericel Announces BARDA Award Valued at up to $197 Million for Procurement and Advanced Development of NexoBrid
Vericel Corporation has secured a $197 million, ten-year contract from the U.S. Biomedical Advanced Research and Development Authority (BARDA) to procure and advance NexoBrid for severe burns and blast trauma treatment. The agreement includes initial procurement, VMI system establishment, manufacturing facility design, and development of a next-generation formulation. Vericel aims to enhance U.S. preparedness for mass casualty events involving se...
04-02 18:40
